HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)-- HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, announced that the company has raised $65 million in Series A funding. The financing will accelerate the clinical development of HAYA's lead long non-coding RNA (lncRNA) targeting candidate HTX-001 in heart failure and the continued expansion of its RNA-guided regulatory genome pipeline development engine. This investment emphasizes investor confidence in HAYA's groundbreaking science and positions the company to deliver on its mission of bringing disease-modifying, precision medicines faster and more efficiently to patients. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly), ATHOS, +ND Capital, Alexandria Venture Investments and LifeLink Ventures, with additional support from existing investors Apollo Health Ventures, Longview Ventures (an affiliate of Broadview Ventures), 4see ventures, BERNINA Bioinvest and Schroders Capital.
"This funding validates our vision for improving the way chronic and complex diseases are treated by creating a new generation of therapies that reprogram disease-driving cell states into healthy ones,' said Samir Ounzain, PhD, HAYA's CEO and co-founder.
Share
'This is a defining moment for HAYA as we are advancing our lead program into the clinic. This funding validates our organization, pioneering approach and vision for improving the way chronic and complex diseases are treated by creating a new generation of therapies that reprogram disease-driving cell states into healthy ones,' said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. 'We're excited that Sofinnova Partners, Earlybird and our syndicate of investors share our vision for the potentially industry changing nature of our platform as we move beyond traditional approaches by leveraging novel therapeutic targets emerging from the regulatory genome.'
The company will use the funds to initiate clinical trials for HTX-001, HAYA's first-in-class lncRNA-targeting therapy for heart failure, initially focused on non-obstructive hypertrophic cardiomyopathy (nHCM). In parallel, the company will strengthen its platform capabilities and expand its pipeline of disease-modifying therapies across multiple therapeutic areas—including pulmonary fibrosis, obesity and age-related common and chronic diseases.
'HAYA's platform unlocks the dark genome's therapeutic potential by targeting disease-driving cell states via long non-coding RNAs. This novel approach opens a new frontier in precision medicine, moving beyond traditional target classes to address disease at its epigenetic and cellular roots. Leading this round alongside Earlybird reflects our deep conviction in the HAYA team and their mission to develop safer, more effective therapies across a broad range of indications, including their lead program in nHCM, as they advance it toward the clinic to address a major unmet need,' noted Henrijette Richter, Managing Partner at Sofinnova Partners.
The core of HAYA's proprietary platform maps and decodes the biology of the regulatory genome, also referred to as the ' genome's dark matter' or 'Dark Genome," which constitutes 98% of the human genome. While the regulatory genome does not code for proteins it is now recognized as the master control layer of gene expression and cell identity. HAYA has developed the most comprehensive atlas of the regulatory genome by combining integrated multimodal functional genomics with a stack of proprietary computational and machine learning methodologies, enabling the precise identification and modulation of pathogenic cell states across diverse diseases. HAYA's regulatory genome platform enables the development of RNA-guided therapeutics with unprecedented precision, speed and scalability. This next-generation approach is designed to go beyond symptom management and directly reprogram the cellular drivers of disease.
To support its strategic growth, HAYA recently assembled an industry-leading C-level suite to drive scalable growth, business and clinical development and expand strategic collaborations with pharmaceutical and technology partners. The company recently announced a partnership with Lilly, one of the largest collaborations to date in the regulatory genome space, focused on RNA-based drug targets for obesity and metabolic disorders.
About HAYA Therapeutics
HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer. The company is using its innovative platform to gain novel insights into the biology of disease cell states and the long non-coding RNAs (lncRNAs) that regulate them. HAYA's lead therapeutic candidate is HTX-001, in development for the treatment of heart failure. HAYA is also developing a pipeline of lncRNA-targeting precision therapies for the cell-specific treatment of diseases in other tissues.
HAYA is headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities in San Diego. For more information on the company, please visit our website at www.hayatx.com. Follow us on X and LinkedIn.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London, and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is deeply established in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Ramp Metals Completes Spring Drill Program and Announces Additional Mineralization at Rush Target
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2025) - Ramp Metals Inc. (TSXV: RAMP) ("Ramp Metals" or the "Company") is pleased to announce that the Company has completed its spring drill program on the Rottenstone SW property. The Company completed 20 drill holes for a total of 4,942 metres. Airborne geophysics using the Xcite HTDEM system, with 100-metre line spacing to provide high-resolution data for target refinement, was also completed over the entire Rottenstone SW property package. Highlights 20 drill holes totalling 4,942 metres were completed, with every metre being sent for assays 8 holes totalling 2,116 metres were drilled at the Ranger target where 73.55 g/t Au over 7.5m was previously discovered in Ranger-001 drill hole 10 holes were drilled at the Rush target with additional VMS style mineralization intersected in 150m step-out 3 holes for a total of 968 metres were drilled at the Rogue target Airborne magnetic and TDEM geophysical survey was completed over the remainder of the Rottenstone SW property using the Xcite HTDEM system "It's exciting to announce that we have completed our spring drill program at the Rottenstone SW property," said Jordan Black, CEO of Ramp Metals. "The program was a huge success completing more holes than originally planned, encountering the quartz diorite package at Ranger and potentially making a new discovery at the Rush target." Figure 1: Rottenstone SW - 2025 Drill Collar Locations To view an enhanced version of this graphic, please visit: Ranger A total of 8 drill holes were completed at the Ranger target (Figure 2). Seven drill holes were completed around the Ranger-001 discovery hole. All 7 holes intersected significant widths of the quartz-diorite package which hosted the previously announced high grade gold intercept of 73.55 g/t Au over 7.5m as reported in the June 17, 2024 News Release. The remaining hole was designed to test a conductor located approximately 1.5km to the north-east, which was identified in the recently completed airborne geophysics (Figure 3). Altered tonalite and metasediments with Pyrrhotite mineralization were encountered. The hole was ended early at 200m due to time constraints. Management believes that further testing is warranted on the eastern Ranger anomalies. Figure 2: Ranger - 2025 Drill Hole Collars and Drill Traces To view an enhanced version of this graphic, please visit: Figure 3: Ranger Drill Collars and Drill Hole Traces with EM To view an enhanced version of this graphic, please visit: Rush A total of 10 holes were drilled at the newly identified Rush VMS target (Figure 4). Semi-massive to massive sulphide mineralization was noted in 5 drill holes, with the presence chalcopyrite and sphalerite being confirmed with a Thermo Scientific™ Niton™ XL5 Plus handheld XRF analyzer. Minor amounts of galena were also noted. Rush-010 intersected net textured to semi-massive sulphide over approximately 4.16m from 21.4m-25.56m (Photo 1). Disseminated to blebby sulphides were also intersected to a depth of approximately 47m (Photo 2). This intersection represents a 150m step-out to the north-east from the initial discovery area where Rush 001, 002, 003, and 009 were drilled. Rush-010 was designed to intercept the outcrop found during the October 2024 field program at depth. Surface rock samples at this outcrop returned values of up to 1.61% copper, 0.79 g/t gold, and 113 g/t silver, as was previously reported in the January 20, 2025 News Release. Figure 4: Rush - 2025 Drill Collars and Drill Hole Traces To view an enhanced version of this graphic, please visit: Photo 1: Rush-010 Boxes 5 & 6 - Net textured to semi-massive mineralization from 21.4-25.56m To view an enhanced version of this graphic, please visit: Photo 2: Rush-010 Boxes 9 & 10 - Disseminated to blebby chalcopyrite mineralization throughout To view an enhanced version of this graphic, please visit: Rogue A total of 3 holes were drilled at the Rogue target (Figure 5). These holes were designed to test structural and conductive targets in an area where soil samples of up to 530.7ppb Au were previously reported in the January 20, 2025 News Release. Pyrrhotite and pyrite mineralization was encountered in two of the three holes (Rogue 005 & 006). Rogue 005 & 006 also encountered sections of potassic and hematite altered diorite and fractures (Photos 3 & 4). During the program, drilling at Rogue was limited due to the overall total number of holes covered by the most recent permit package. The Company believes that the Rogue target warrants further exploration to explain the source of the highly anomalous gold in soils. Figure 5: Rogue - 2025 Drill Collar Locations and Drill Hole Traces To view an enhanced version of this graphic, please visit: Photo 3: Rogue-005 Boxes 25 & 26 - Potassic alteration of diorite and hematite altered fractures To view an enhanced version of this graphic, please visit: Photo 4: Rogue-006 Boxes 61 & 62 - Coarse-grained diorite with potassic alteration To view an enhanced version of this graphic, please visit: Geophysics The Company has completed a magnetic and TDEM survey over the remainder of the Rottenstone SW property using the Xcite HTDEM system. A total of 3,342 line-km was flown at 100m spacing to provide a high-resolution Mag and EM dataset over the entire property. Data is currently being processed, and the Company will provide a further update once the data processing is completed. Next Steps With the present forest fire situation in northern Saskatchewan, the Company felt it prudent to relocate all drill core to a facility in the Prince Albert area to safely complete processing and preparation for assays. The first shipment of samples has been delivered and is being analyzed at Bureau Veritas Commodities Canada Ltd. ("BV") in Vancouver, BC. All remaining core has been fully logged and is currently being cut and sorted for shipping. The Company plans to return to the Rottenstone SW property for further mapping and sampling once the data from the airborne geophysics and drill programs have been analyzed, and the fire risk has subsided. A ground geophysics program is also planned for the summer to help better define the conductive targets on the property. An amendment to the current permits requesting up to 30,000m of additional drilling and a 30-person camp is being prepared and is expected to be submitted shortly. Acknowledgements Ramp Metals would like to thank the Lac La Ronge Indian Band and all land users for their continued support and working closely with the Company through the permitting process. The Company would also like to thank all the contractors who made the 2025 winter/spring drill program a success. Drilling: Flamingo Drilling through Athabasca Catering Limited Partnerships Geology and Geophysics: Axiom Exploration Group Ltd. (Mikaela Miller, Craig Cubbon, Logan Anaka) Accommodations: Thompson's Resort - Adventure Destinations Flight Services: Heli-Recon Aerial Support Services Inc. and Osprey Wings Ltd. Fuel Services: Millsap Fuel Distributors Ltd. Local Contractors: Cecil Mcleod, Alex Mcleod, Bradley McKenzie, Ethan Ballantyne, Joey McKenzie, Chris Roberts, Joe Stanley, Jimmy McKenzie, Riley Provencher Quality Assurance/Quality Control Uncut whole NQ drill core was analyzed by a Thermo Scientific™ Niton™ XL5 Plus handheld XRF, operated by Ramp Metals staff on site. The Portable X-Ray Fluorescence ("pXRF") data is exploratory in nature and is used predominantly as an internal workflow to assist in target prioritization and mineral identification through an early phase of exploration investigation. pXRF data is not provided as it is not an indicator of representative geochemistry of the entire rock mass and therefore should only be viewed as an initial screening prior to laboratory assays. Drill core is currently being sampled and cut by diamond saw. Samples will be shipped as they are processed for laboratory analysis at BV, an internationally recognized and ISO 17025:2017 accredited analytical services provider, at its Vancouver, BC laboratory. Drill core samples are marked in maximum intervals of up to 1.5m and cut in half using a diamond saw with half sent for assay and the other half saved for reference. Samples are then bagged and zip-tied, with 15 bagged samples placed into sealed rice bags and then 20 rice bags placed in mega bags for transport to BV. Sample QA/QC procedures were applied by inserting a regular and systematic schedule of standards, blanks and duplicates into the sample stream. Control samples consisting of certified reference samples and blank samples were systematically inserted into the sample stream and analyzed as part of the Company's QA/QC protocol at a rate of 1:15 or better in addition to BV's internal quality assurance programs. Rock samples are prepared using the PRP70-250 package, where samples are weighed, dried, and crushed to greater than 70% passing a 2mm sieve, then pulverized to greater than 85% passing 75 microns. Samples are analyzed in accordance with BV's MA300 and FA330 packages, for both multi-element ICP analysis (0.25 g, multi-acid and ICP-ES analysis) and gold analysis by fire assay (30g fire assay with AAS finish). Gold returning >10ppm is automatically analyzed by gravimetric method in accordance with BV's standard of practice. Qualified Person Brett Williams, VP Operations and Senior Geologist for Ramp Metals, and a "qualified person" under National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed and approved the technical content in this news release. About Ramp Metals Inc. Ramp Metals is a grassroots exploration company with a focus on a potential new Saskatchewan gold district. The Company currently has a new high-grade gold discovery of 73.55 g/t Au over 7.5m at its flagship Rottenstone SW property. The Rottenstone SW property comprises 32,715 hectares and is situated in the Rottenstone Domain. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. FORWARD-LOOKING STATEMENTS This news release contains "forward-looking statements" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved". The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding the Company's exploration activities. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: requirements for additional capital; future prices of minerals; changes in general economic conditions; changes in the financial markets and in the demand and market price for commodities; other risks of the mining industry; the inability to obtain any necessary governmental and regulatory approvals; changes in laws, regulations and policies affecting mining operations; hedging practices; and currency fluctuations. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. For further information, please contact: Ramp Metals Inc. Jordan BlackChief Executive Officerjordaneblack@ Prit SinghDirector905 510 7636 To view the source version of this press release, please visit
New York Post
4 days ago
- New York Post
An ‘international gold rush' could be on its way — and it's because of a ‘significant' discovery in Finland
A single drill hole in Finland has unearthed a significant gold deposit, sending shockwaves through the global markets in what could likely be a new international gold rush. The significant discovery was confirmed to be found in bedrock samples taken from the site in February along the Karelian Gold Line in Ukkolanvaara, according to mining and exploration company Endomines. The initial drill hole, named UKKO-001, hit three major gold-rich sections and has exceeded expectations, the company's CEo, Kari Vyhtinen, said. 'An impressive result was achieved with the very first drill hole,' he notes. 'The result confirms the great gold potential of the Ukko-deposit in Ukkolanvaara. Three such high-grade gold zones in the same drill hole is something we have never seen before in exploration.' Vyhtinen said their plan was to conduct only a three-to four-week research campaign in the area, but the company has now decided to continue the investigations indefinitely. 'The iron deposit in Ukkolanvaara is very extensive,' he adds. 'Additionally, observations of visible gold in several drill holes indicate that gold is present over a wider area in connection with the iron deposit.' The significant discovery was confirmed to be found in bedrock samples taken from the site in February along the Karelian Gold Line in Ukkolanvaara. Roman Bodnarchuk – The initial drill hole, named UKKO-001, hit three major gold-rich sections and has exceeded expectations. Dmitry Naumov – Vyhtinen believes the gold discovery will prove to be 'significant.' The company's findings show various samples of gold ranging upwards of nearly 10 grams per metric ton. To date, 12 holes have been drilled, with more results pending.
Associated Press
7 days ago
- Associated Press
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001's Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, including those with BRAC1 and BRCA2 mutations LAWRENCEVILLE, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced positive data from the Company's Phase 2 OVATION 2 Study showing that treatment with IMNN-001 in women with newly diagnosed advanced ovarian cancer resulted in consistent, clinically meaningful improvements in several key endpoints across treatment groups, including overall survival (OS), progression-free survival (PFS), chemotherapy response score and surgical response. Treatment with IMNN-001 also showed a favorable safety profile, with no reports of serious immune-related adverse events. The full results are being presented today in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, and simultaneously published in the peer-reviewed journal Gynecologic Oncology . Participants with newly diagnosed advanced epithelial ovarian cancer in the Phase 2 OVATION 2 Study (n=112) were randomized 1:1 to evaluate the safety and efficacy of IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) compared to standard of care (SoC) N/ACT alone, with a median follow-up of 31 months. The data being presented today highlight the consistent results achieved across all treatment groups, demonstrating: Median 13-month increase in OS (46 vs. 33 months) and median 3-month increase in PFS (14.9 vs. 11.9 months) in IMNN-001 treatment arm compared to standard of care alone. Better therapeutic effect observed with IMNN-001 treatment compared to the control arm (p=0.0375), as shown by mean 6.5-month extension of time free of progression or death (PFS + OS) captured in totality of treatment effect. Use of poly ADP-ribose polymerase (PARP) inhibitors as part of maintenance therapy further enhanced outcomes, with median OS not yet reached in IMNN-001 treatment arm after >5 years compared to 37 months on standard of care. Chemotherapy response score highlights double the response rate of a complete or near complete histopathological response following treatment with 26.1% in the IMNN-001 treatment arm compared to 13.0% in the control arm. Surgical response rate of no macroscopic residual tumor left after surgery 64.6% in the IMNN-001 treatment arm compared to 52.1% in the control arm. Hazard ratio of 0.78 in study participants who are homologous recombination proficient (HRP) and hazard ratio of 0.42 in women positive for homologous recombination deficiency (HRD+), including BRCA1 or BRCA2 mutations, suggesting increased therapeutic activity. IMNN-001 was generally safe and well tolerated, with no reports of cytokine release syndrome, systemic toxicity or serious immune-related adverse events (AEs). The most common AEs primarily included abdominal pain, nausea and vomiting. 'These data highlighting the consistency of results across all treatment groups are a true testament to the power of our TheraPlas technology and the potential of IMNN-001 to transform the treatment paradigm of women who are newly diagnosed with advanced ovarian cancer and in desperate need of new treatment options,' said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. 'Results were consistent across a variety of participants, including women who receive PARP inhibitors, who are HRP and HRD positive, and who have BRCA1 and BRCA2 mutations. We are grateful for the continued support and participation of study participants and investigators and look forward to advancing our pivotal Phase 3 OVATION 3 trial of IMNN-001, with the first two trial sites recently initiated.' The OVATION 2 Study oral presentation and journal manuscript will both be available on the 'Scientific Presentations' page of IMUNON's website at . About the Phase 2 OVATION 2 Study OVATION 2 evaluated the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following N/ACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. This open-label study enrolled 112 patients who were randomized 1:1 and evaluated for safety and efficacy to compare N/ACT plus IMNN-001 versus standard-of-care N/ACT. In accordance with the study protocol, patients randomized to the IMNN-001 treatment arm could receive up to 17 weekly doses of 100 mg/m2 in addition to N/ACT. As a Phase 2 study, OVATION 2 was not powered for statistical significance. Additional endpoints included objective response rate, chemotherapy response score and surgical response. About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer. About Epithelial Ovarian Cancer Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately 70% are diagnosed in advanced Stage III/IV. Epithelial ovarian cancer is characterized by dissemination of tumors in the peritoneal cavity with a high risk of recurrence (75%, Stage III/IV) after surgery and chemotherapy. Since the five-year survival rates of patients with Stage III/IV disease at diagnosis are poor (41% and 20%, respectively), there remains a need for a therapy that not only reduces the recurrence rate but also improves overall survival. The peritoneal cavity of advanced ovarian cancer patients contains the primary tumor environment and is an attractive target for a regional approach to immune modulation. About IMUNON IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit . Forward-Looking Statements IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing and enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety profile of our product candidates, and the Company's plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'estimate,' 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. Contacts:
